Bragg-Gresham Jennifer L, Annadanam Surekha, Gillespie Brenda, Li Yiting, Powe Neil R, Saran Rajiv
Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA.
Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA.
J Gen Intern Med. 2024 Nov 18. doi: 10.1007/s11606-024-09185-9.
Guidelines currently recommend annual screening for albuminuria only among persons with diabetes mellitus (DM). There is no guidance about albuminuria screening in those with other important risk factors for chronic kidney disease (CKD), such as hypertension and/or family history of kidney disease. We sought to create a risk score that predicts the likelihood of albuminuria in adults without diabetes to prompt earlier detection and management of CKD.
Data from 44,322 participants without diabetes, aged 18 + years from the National Health and Nutrition Examination Surveys 1999-2020 were analyzed. Survey-weighted logistic regression was used to assess associations between individual characteristics and presence of albuminuria (urinary albumin to creatinine ratio [UACR] ≥ 30 mg/g), including interaction terms, in three separate models. The sample was divided equally into development and validation data sets. C-statistics were used to assess model fit.
The prevalence of albuminuria was 9.7% in the US adult population. Higher odds of albuminuria among the non-diabetic population were observed in females, non-Hispanic Black, and smokers, as well as those with low eGFR, hypertension, cardiovascular disease, prediabetes, low HDL cholesterol, and high uric acid levels. Age showed a J-shaped relationship with albuminuria, with lowest odds for ages 25-64 years. The C-statistic was 0.756 for the developmental and 0.752 for the validation set of the final model. Using this model, screening individuals with a predicted probability of ≥ 5% would capture 85% of individuals with albuminuria.
These results suggest that it may be helpful to use a risk score framework for albuminuria screening in people without DM to encourage earlier detection and management of CKD. Longitudinal studies are warranted to confirm this approach along with evaluation of its cost effectiveness.
目前的指南仅建议对糖尿病患者进行年度蛋白尿筛查。对于慢性肾脏病(CKD)的其他重要危险因素,如高血压和/或肾病家族史患者,尚无蛋白尿筛查的指导建议。我们试图创建一个风险评分系统,以预测无糖尿病成年人出现蛋白尿的可能性,从而促进CKD的早期检测和管理。
分析了1999 - 2020年美国国家健康与营养检查调查中44322名年龄在18岁及以上的无糖尿病参与者的数据。在三个独立模型中,采用调查加权逻辑回归评估个体特征与蛋白尿(尿白蛋白与肌酐比值[UACR]≥30 mg/g)之间的关联,包括交互项。样本被平均分为开发数据集和验证数据集。使用C统计量评估模型拟合度。
美国成年人群中蛋白尿的患病率为9.7%。在非糖尿病人群中,女性、非西班牙裔黑人、吸烟者以及估算肾小球滤过率(eGFR)低、患有高血压、心血管疾病、糖尿病前期、高密度脂蛋白胆固醇低和尿酸水平高的人群出现蛋白尿的几率更高。年龄与蛋白尿呈J形关系,25 - 64岁人群出现蛋白尿的几率最低。最终模型的开发数据集C统计量为0.756,验证数据集为0.752。使用该模型,对预测概率≥5%的个体进行筛查,可发现85%的蛋白尿患者。
这些结果表明,对于无糖尿病的人群,使用风险评分框架进行蛋白尿筛查可能有助于促进CKD的早期检测和管理。有必要进行纵向研究以证实这种方法,并评估其成本效益。